Griffin Asset Management’s ImmunityBio IBRX Stock Holding History

Griffin Asset Management’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-1	Closed	–	–	336
2019 Q2	$0	Buy	+1	New	+$1	﹤0.01%	564

Other funds holding IBRX

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WCM

Wildcat Capital Management New York $106M AUM 0.1% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

HKAM

Horizon Kinetics Asset Management New York $9.23B AUM 27.52% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Griffin Asset Management's IBRX Position: Q3 2019 in Review

Griffin Asset Management sold out of ImmunityBio (IBRX) in Q3 2019, closing a stake of 1 share.

Griffin Asset Management first reported a position in IBRX in Q2 2019 and held it in 1 quarter. The position peaked at $0 in Q2 2019. 39 funds tracked by Wall St. Rank hold IBRX as of Q3 2019.

Griffin Asset Management reported no remaining ImmunityBio position as of Q3 2019 after selling out during the quarter.
Griffin Asset Management sold 1 ImmunityBio share in Q3 2019.
Griffin Asset Management first reported a position in ImmunityBio in Q2 2019 and held it in 1 quarter.
Griffin Asset Management's ImmunityBio position peaked at $0 in Q2 2019.
39 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2019.

Based on Griffin Asset Management's 13F filing for Q3 2019, filed 5 Nov 2019.